BIIB Stock Recent News

Biogen Inc. (BIIB) came out with quarterly earnings of $3.44 per share, beating the Zacks Consensus Estimate of $3.42 per share. This compares to earnings of $2.95 per share a year ago.

Sales of an Alzheimer's disease treatment were better than expected, but that and a quarterly beat wasn't enough to offset below-consensus EPS outlook.

Biogen posted fourth-quarter revenue and profit that topped expectations as its cost cuts showed progress and new products, including its breakthrough Alzheimer's treatment Leqembi, saw growth.  The biotech company issued a full-year 2025 adjusted earnings outlook of $15.25 to $16.25 per share, which fell short of the $16.34 per share that Wall Street was expecting.

Biogen forecast 2025 profit below Wall Street expectations on Wednesday, hurt by a strong dollar and fierce competition for its drugs to treat multiple sclerosis.

Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus

Biogen Inc. BIIB will release its fourth-quarter financial results, before the opening bell, on Wednesday, Feb. 12, 2025.

We focus on biotech stocks like VRTX, GILD, BIIB, ALNY and MRNA, which are scheduled to report this week.

Beyond analysts' top -and-bottom-line estimates for Biogen (BIIB), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

Biogen (BIIB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The EC requests CHMP to reassess new safety data that emerged after the positive opinion recommending the approval of BIIB/Eisai's Leqembi in the EU for early AD.